Consultant, Department of Nephrology, Saraswati Kidney Care Center, Nagpur, and JNMC, Sawangi, Wardha, Maharashtra, India, Corresponding Author.
Consultant, Department of Nephrology, Saraswati Kidney Care Center, Nagpur, and JNMC, Sawangi, Wardha, Maharashtra, India.
J Assoc Physicians India. 2023 Sep;71(9):56-60. doi: 10.59556/japi.71.0313.
Maintenance hemodialysis (MHD) patients are at increased risk of contracting coronavirus disease 2019 (COVID-19). Vaccine against COVID-19 offers the benefit of protection from severe illness. In this study, we assessed the humoral response after two doses of the COVISHIELD vaccine in MHD patients.
In a prospective cohort study, the humoral response with two doses of the COVISHIELD vaccine was assessed after 14 ± 2 days of the second dose. The COVIPROTECT antibody titers against the spike protein were measured using the electrochemiluminescence immunoassay (ELECSYS, Roche Diagnostics International Ltd.). Data were analyzed to determine the predictors of antibody response.
Between February and October 2021, 50 MHD patients were assessed. The mean age was 55.8 ± 10.8 years, and 72% were males. A total of 48 (96%) MHD patients have seropositivity. The median level of spike protein antibody was 579 U/mL [interquartile range (IQR25-75) 166-1852.75]. Compared to patients with no COVID-19 infection history, the median levels of antibodies were significantly higher in those with a history of COVID-19 (1047 vs 297 U/mL, p = 0.011). The antibody titers did not differ by age ( = 0.269), presence of comorbidities such as hypertension ( = 0.341), diabetes mellitus ( = 0.719) or ischemic heart disease (IHD) ( = 0.695), dialysis vintage ( = 0.660), and timing of diagnosis of COVID-19 in relation to vaccination ( = 0.261). Adverse events (AEs) occurred in one-third of patients that were mild and self-limiting. No serious AEs were observed in any patient.
In MHD patients, two doses of the COVISHIELDTM vaccine induced a substantial humoral response. Prior history of COVID-19 resulted in a higher antibody response. Thus, the COVISHIELDTM vaccine is efficacious and safe for use in patients with MHD. How to cite this article: Balwani MR, Pasari AS, Bawankule C, Humoral Response After Two Doses of COVISHIELD Vaccine in Patients Undergoing Maintenance Hemodialysis. J Assoc Physicians India 2023;71(9):56-60.
维持性血液透析（MHD）患者感染 2019 年冠状病毒病（COVID-19）的风险增加。COVID-19 疫苗可提供预防重症的益处。在这项研究中，我们评估了 MHD 患者接种两剂 COVISHIELD 疫苗后的体液反应。
在一项前瞻性队列研究中，在第二剂后 14 ± 2 天评估了两剂 COVISHIELD 疫苗的体液反应。使用电化学发光免疫分析（ELECSYS，罗氏诊断国际有限公司）测量针对刺突蛋白的 COVIPROTECT 抗体滴度。分析数据以确定抗体反应的预测因素。
2021 年 2 月至 10 月期间，评估了 50 名 MHD 患者。平均年龄为 55.8 ± 10.8 岁，72%为男性。共有 48 名（96%）MHD 患者呈血清阳性。刺突蛋白抗体的中位水平为 579 U/mL[四分位距（IQR25-75）166-1852.75]。与无 COVID-19 感染史的患者相比，有 COVID-19 感染史的患者的抗体中位水平显著更高（1047 与 297 U/mL，p=0.011）。抗体滴度与年龄（=0.269）、高血压（=0.341）、糖尿病（=0.719）或缺血性心脏病（IHD）（=0.695）等合并症的存在、透析龄（=0.660）以及 COVID-19 与疫苗接种的时间关系（=0.261）无关。三分之一的患者发生了轻度且自限性的不良事件（AE）。任何患者均未观察到严重 AE。
在 MHD 患者中，两剂 COVISHIELDTM 疫苗诱导了大量的体液反应。既往 COVID-19 感染史导致更高的抗体反应。因此，COVISHIELDTM 疫苗对 MHD 患者有效且安全。
